Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

Table 5 Mean increase in scores from baseline to 90 day in the KyberSept Trial by subgroups: all-survivors

	Mobility		Physical activity		Communications/speech		Level of alertness		Energy level		Overall QoL		Karnofsky
Parameter	Placebo	AT III	Placebo	AT III	Placebo	AT III	Placebo	AT III	Placebo	AT III	Placebo	AT III	Placebo	AT III
SAPS II risk
Moderate	49 ± 23	51 ± 24	48 ± 22	50 ± 23	43 ± 35	48 ± 33	43 ± 34	47 ± 33	47 ± 22	49 ± 22	50 ± 23	50 ± 21	49 ± 18	49 ± 18
High	51 ± 24	52 ± 23	50 ± 22	51 ± 22	58 ± 31	61 ± 30	56 ± 28	60 ± 29	48 ± 23	51 ± 22^† 53 ± 22		54 ± 23	44 ± 19	46 ± 19
Very high	47 ± 26	52 ± 26	44 ± 25	50 ± 25	59 ± 35	66 ± 29	59 ± 33	67 ± 28^†	46 ± 23	51 ± 24	50 ± 25	55 ± 25	41 ± 21	43 ± 19
Admitting diagnosis
Respiratory	50 ± 25	54 ± 23^†	48 ± 23	52 ± 23	51 ± 35	59 ± 33	52 ± 32	58 ± 32^†	46 ± 23	51 ± 22^†	52 ± 24	55 ± 22	46 ± 19	49 ± 18
Digestive	50 ± 23	52 ± 24	49 ± 23	50 ± 23	55 ± 35	60 ± 31	54 ± 33	59 ± 31	46 ± 24	49 ± 22^†	52 ± 23	51 ± 24	45 ± 19	46 ± 19
Genitourinary	46 ± 21	43 ± 26	46 ± 20	43 ± 25	40 ± 36	40 ± 34	40 ± 34	37 ± 34	49 ± 19	44 ± 22	48 ± 21	44 ± 25	47 ± 20	45 ± 18
Injury	51 ± 24	47 ± 27	52 ± 22	48 ± 26	58 ± 26	55 ± 29	55 ± 27	59 ± 29	49 ± 21	52 ± 26^†	53 ± 18	53 ± 24	67 ± 21	70 ± 19
Other	48 ± 25	51 ± 24	48 ± 23	51 ± 23	53 ± 33	56 ± 31	52 ± 30	56 ± 31	48 ± 23	53 ± 22	51 ± 24	54 ± 21	69 ± 21	68 ± 18
Concomitant heparin
No	44 ± 22	48 ± 24^†	43 ± 21	48 ± 22^*	42 ± 36	51 ± 31^†	42 ± 33	49 ± 31	43 ± 22	49 ± 22^†	47 ± 22	51 ± 23	43 ± 19	43 ± 19
Yes	51 ± 24	53 ± 24	50 ± 23	52 ± 24	55 ± 33	60 ± 32^†	54 ± 31	59 ± 31^*	48 ± 23	52 ± 22^†	52 ± 23	54 ± 23	46 ± 19	46 ± 19

Values are expressed as mean ± SD. ^*P < 0.05 versus placebo; ^†P < 0.1 versus placebo. Mean scores represent changes between the 90-day and the baseline values for all-survivors (those in hospital 90 days from study enrollment, or closest time point to 90 days [last observation carried forward analysis; see text]). All mean scores increased (higher scores indicate better quality of life [QoL]). AT, antithrombin.

ISSN: 1364-8535